3 news items
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
GLYC
6 May 24
million, compared to $41.8 million as of December 31, 2023.
The company’s R&D expenses increased to $6.0 million from $5.4
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GLYC
6 May 24
, 2023.
R&D Expenses
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GLYC
27 Mar 24
.
R&D Expenses: The company's research and development expenses
- Prev
- 1
- Next